The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS ...
A Blue Bell startup is studying whether stabilizing mitochondria can slow progression in neurodegenerative disease.
I AM ALS announced a major milestone in its Push for Progress campaign: thanks to our community of advocates and partners, we've secured $313 million in funding for ALS research in the 2026 federal ...
WASHINGTON (AP) — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by ...
The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...
A study is exploring why athletes, first responders, and other high performers face an increased risk of developing ALS.
NEW ORLEANS--(BUSINESS WIRE)--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) ...
(CNN) — You can watch Dr. Sanjay Gupta’s full report, plus his answers to your questions about this, on Erin Burnett OutFront tonight at 7pmET. Staring at a computer screen, Mark focuses deeply, his ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results